Physician profile
Reynerio E Perez Ramirez
NPI 1003049289
$6,722.74
in general payments reported to CMS, 2019-2025
21 companies · $725 in 2025
The $725 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,168 · 2020: $122 · 2021: $1,127 · 2022: $1,310 · 2023: $1,426 · 2024: $845 · 2025: $725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,996.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,995.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,329.72 | 2019-2024 | Gallant, Aveir, Mitraclip |
| E.R. Squibb & Sons, L.L.C. | $826.36 | 2019-2023 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $795.73 | 2020-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $637.77 | 2019-2024 | Farxiga |
| Janssen Pharmaceuticals, INC | $533.96 | 2019-2024 | Xarelto |
| Amgen INC. | $518.30 | 2019-2024 | Repatha |
| Boston Scientific Corporation | $407.75 | 2019-2025 | Watchman Access System, Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $388.21 | 2019-2025 | Lifevest |
| Bayer Puerto Rico INC. | $313.08 | 2023-2025 | Kerendia |
| Medtronic, INC. | $185.67 | 2023-2025 | Micra, Mycarelink |
| Pbg Puerto Rico LLC | $154.48 | 2019-2025 | |
| Pfizer Pharmaceuticals LLC | $118.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $107.03 | 2025 | |
| Eli Lilly Export S.A. Puerto Rico Branch | $100.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $80.18 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $67.93 | 2025 | Veltassa |
| Scpharmaceuticals INC. | $58.96 | 2025 | |
| Merck Sharp & Dohme LLC | $57.35 | 2023-2024 | Verquvo, Winrevair |
| Dexcom, INC. | $20.07 | 2024 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $14.29 | 2019 | |
| Pfizer INC. | $7.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reynerio Perez Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.